The effects of whole soil biotic communities on plants is a result of positive and negative interactions from a complex suite of mutualists and pathogens. However, few experiments have evaluated the composite effects of whole soil biotic communities on plant growth and disease resistance. We conducted a factorial greenhouse experiment with 14 Rhododendron species grown with and without live conspecific soil biota and with and without the disease, Phytophthora cinnamomi. We tested the prediction that the presence of whole soil biotic communities influences survival in the presence of disease. We also explored functional trait correlations with disease susceptibility across the phylogeny.  https://www.selleckchem.com/products/baxdrostat.html  The presence of live soil biota led to higher survival in the presence of disease compared with sterilized soils, and the direction of this effect was consistent for seven species across four clades. The presence of live soil biota also significantly reduced plant growth rate and decreased shoot biomass, relative to plants grown in sterilized soil, indicating that live soil biota might influence plant allocation strategies. We found that Rhododendron species with higher Root Shoot Ratios were less susceptible to Phytophthora, suggesting that water relations influence disease susceptibility. Our findings that disease resistance and susceptibility occur independently across multiple clades and that whole soil biotic communities consistently enhance disease resistance across clades, suggest that soil biota may play an important role in disease resistance and can moderate disease-induced mortality.Long-term aerosol optical thickness (AOT) composited data (2002-2017) derived from Moderate Resolution Imaging Spectroradiometer (MODIS) on the Terra and Aqua spacecraft was used to evaluate the temporal and spatial variability of aerosol in Xiamen city by using wavelet analysis, and the relationship between the surface mass concentrations of particulate matter with aerodynamic diameters less than 2.5 μm (PM2.5) and the AOT was analyzed by using linear regression. The results showed that AOT increased gradually from 2002 to 2011, and then decreased. AOT displayed a significant 9-month periodicity in AOT was inferred wavelet analysis. AOT also showed significant annual variability in response to changes in weather and aerosol pollution. We observed highest AOT values in April, with a monthly mean of 1.00 ± 0.18. Lowest values were observed in December, with a mean AOT of 0.52 ± 0.11. Multi-year monthly AOT fluctuations were lowest in January with a low variation coefficient (0.14), and the largest fluctuations appeared in July with a high variation coefficient (0.29). Higher AOT values (~ 1.1) were predominantly located in the southern urban areas of Xiamen and lower AOT values (~ 0.3) were mainly located in northern rural regions. The aerosol pollution was serious in April with the smallest spatial variation coefficient of 0.25, and the highest spatial variation coefficient appeared in July. Highest intraannual variability predominantly occurred in the high-value areas in the center of Xiamen. AOT values remained high in Xiamen Island throughout the year with a multi-year mean of 0.87. There was a moderate correlation between ground-based PM2.5 and MODIS AOT. Therefore, we confirm the suitability of MODIS AOT to accurately estimate PM2.5 concentration and evaluate the temporal and spatial characteristics of air quality in Xiamen.
  Coronavirus disease 2019 (COVID-19) is expected to continue to cause worldwide fatalities until the World population develops 'herd immunity', or until a vaccine is developed and used as a prevention. Meanwhile, there is an urgent need to identify alternative means of antiviral defense. Bacillus Calmette-Guérin (BCG) vaccine that has been recognized for its off-target beneficial effects on the immune system can be exploited to boast immunity and protect from emerging novel viruses.
 
  We developed and employed a systems biology workflow capable of identifying small-molecule antiviral drugs and vaccines that can boast immunity and affect a wide variety of viral disease pathways to protect from the fatal consequences of emerging viruses.
 
  Our analysis demonstrates that BCG vaccine affects the production and maturation of naïve T cells resulting in enhanced, long-lasting trained innate immune responses that can provide protection against novel viruses. We have identified small-molecule BCG mimics, including antiviral drugs such as raltegravir and lopinavir as high confidence hits. Strikingly, our top hits emetine and lopinavir were independently validated by recent experimental findings that these compounds inhibit the growth of SARS-CoV-2 in vitro.
 
  Our results provide systems biology support for using BCG and small-molecule BCG mimics as putative vaccine and drug candidates against emergent viruses including SARS-CoV-2.
 Our results provide systems biology support for using BCG and small-molecule BCG mimics as putative vaccine and drug candidates against emergent viruses including SARS-CoV-2.
  Cervical cancer (CC) is most often caused by the human papillomavirus (HPV). In principle, these ties to the virus should make HPV tumors a relatively easy target for clearance by the immune system. However, these HPV-associated tumors have evolved strategies to escape immune attack. Checkpoint inhibition immunotherapy, which has had remarkable success in cancer treatment, has the potential to overcome the immune escape in CC by harnessing the patient's own immune system and priming it to recognize and kill tumors. Recent work involving PD-1/PD-L1 inhibitors in CC lends credence to this belief, as pembrolizumab has shown evidence of clinical efficacy and consequently been granted accelerated approval by the FDA. That being said, the oncologic outcomes following monotherapy with these biologics have mostly been modest and variable, and this can be attributed to alternative resistance mechanisms to tumor response. The use of therapies that stimulate immune responses via checkpoint-independent activation will by the FDA. That being said, the oncologic outcomes following monotherapy with these biologics have mostly been modest and variable, and this can be attributed to alternative resistance mechanisms to tumor response. The use of therapies that stimulate immune responses via checkpoint-independent activation will therefore augment release of T cell inhibition by checkpoint inhibitors for stronger and more sustained clinical responses. Such a combinatorial approach holds promise for weak- or non-responders to checkpoint therapies as supported by evidence from various, recent pre-clinical, and preliminary clinical studies.